Personalised medicine

Our Projects

The development of new medicines and therapies is accelerating due to new technologies and insights. At the same time, we are not getting the optimal effect from existing and new medicines and treatments. There is a “gap” between knowledge and application. The result is that medicine and treatment are often not optimally tailored for the patient. It’s time for a breakthrough; professionally closing this implementation gap through personalised medicine.


In the implementation cell we go through the following steps:
1. Initiation
2. Breakthrough intention
3. Contract implementation
4. Implementation study
5. Scaling up


Implementation cell

An implementation cell is a temporary public / private partnership to close a specific implementation gap more quickly. This cell consists of a team of professionals from the medical domain (pharma, medicine, medical technology and molecular biology), the social domain (social, legal, ethical and behavioral matters), data science and (SME) entrepreneurs. These parties recognize that unique competencies are required to meet the implementation challenge. They make an effort to realize the values, which they share jointly, through a prospective practical study (clinical trial / cohort study) in respect for each other and our common interests.

TOMi offers a structured and systematic way to close the implementation gap. We do this by setting up implementation cells, per (medical) indication, function or hypothesis. The TOMi implementation cells develop applications such as biomarkers and precision diagnostics with which more effectiveness can be achieved from existing medicines and treatments, in joint decision-making with the patient (patient value).

Do you want to participate?

What implementation gap in personalised medicine would you like to fix yourself?

Which (potential) personalised medicine projects have not continued or been stopped due to implementation barriers?

Which (potential) personalised medicine projects are ongoing or upcoming and would benefit from better access and collaboration?